Annexon (ANNX) Capital Expenditures (2019 - 2026)
Annexon's (ANNX) quarterly Capital Expenditures came in at -$275000.0 in Q1 2026, down 471.62% year-on-year from $74000.0 in Q1 2025, and down 105.32% quarter-over-quarter from $5.2 million in Q4 2025.
Annexon (ANNX) Capital Expenditures (2019 - 2026) Analysis & Trends
Annexon's Capital Expenditures history runs 8 years deep, the most recent figure standing at -$275000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures fell 471.62% year-over-year to -$275000.0 in Q1 2026; TTM through Mar 2026 was $5.0 million, a 1007.59% increase from a year earlier, with the FY2025 full-year figure at $5.3 million, up 35306.67% from the prior year.
- Capital Expenditures retreated to -$275000.0 in Q1 2026 per ANNX's latest filing, from $5.2 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $5.2 million in Q1 2022 and bottomed at -$5.1 million in Q2 2022.
- The 5-year median for Capital Expenditures is $19000.0 (2023), against an average of $380400.0.
- Across the five-year window, Capital Expenditures surged 86133.33% in 2025 and tumbled 471.62% in 2026, its largest moves.
- Year by year, Capital Expenditures stood at -$8000.0 in 2022, then surged by 187.5% to $7000.0 in 2023, then slipped by 14.29% to $6000.0 in 2024, then jumped by 86133.33% to $5.2 million in 2025, then slumped by 105.32% to -$275000.0 in 2026.
- Per Business Quant, the three latest ANNX Capital Expenditures figures stand at -$275000.0 (Q1 2026), $5.2 million (Q4 2025), and $48000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 786,000.00 |
| 10 | Annexon | 1.02 Bn | 798.41 Mn | - | -275,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -275,000.00 |
| Mar 31, 2026 | -275,000.00 |
| Dec 31, 2025 | 5.17 Mn |
| Dec 31, 2025 | 5.17 Mn |
| Sep 30, 2025 | 48,000.00 |
| Sep 30, 2025 | 48,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Mar 31, 2025 | 74,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 361,000.00 |
| Mar 31, 2024 | 361,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Sep 30, 2023 | 19,000.00 |
| Jun 30, 2023 | 162,000.00 |
| Jun 30, 2023 | 162,000.00 |